Peripheral analgesics |
Rather not |
[Evidence level B (paracetamol), evidence level D for other drugs, recommendation strength ↓, strong consensus] |
Opiates and opiate agonists |
Virtually never |
[Evidence level A for kappa agonists, evidence level D for µ- agonists and classical opiates, evidence level A for opiate antagonists, recommendation strength ↓↓, strong consensus] |
Spasmolytics |
In most patients |
[Evidence level A, recommendation strength ↑, strong consensus] |
Soluble fiber |
In some patients |
[Evidence level A, recommendation strength ↑, strong consensus] |
Tricyclic antidepressants |
In some patients |
[Evidence level A, recommendation strength ↑, strong consensus] |
SSRIs |
In some patients |
[Evidence level A, recommendation strength ↑, strong consensus] |
5-HT3 antagonists |
In few selected patients |
[Evidence level A, recommendation strength ↑, consensus] |
Probiotics |
In some patients |
[Evidence level A, recommendation strength ↑, strong consensus] |
Antibiotics |
Rather not |
[Evidence level A, recommendation strength ↓, consensus] |
Pregabalin/gabapentin |
Rather not |
[Evidence level B , recommendation strength ↓, strong consensus] |
Phytotherapeutics |
In some patients |
[Evidence level A, recommendation strength ↑, strong consensus] |
Aloe vera |
Rather not |
[Evidence level A, recommendation strength ↓, strong consensus] |
Pancreatic enzymes |
Virtually never |
Þ [Evidence level D, recommendation strength ↓↓, strong consensus] |